Home / Letter From The Editor / August 13, 2016

August 13, 2016

Aug 13, 2016


Last week the FDA announced that they were going to approve 6 different manufacturers for the production of rosuvastatin calcium, the generic version of Crestor. It appears that the FDA has decided that if they let more companies produce the generic, the price may not be as high to start with. This is a good signal for patients that have been successful with Crestor in the past. However, for those patients who have not responded well to rosuvastatin or any of the other statins, there is a whole new class of drugs that prescribers now have available.

This class, known as the PCSK9 Inhibitors, holds a lot of promise for many patients who have been unsuccessful at lowering their LDLs.

This week, we have an interview that Steve Freed, our publisher, did with Dr. Robert Eckel, the Charles A. Boettcher Endowed Chair in Atherosclerosis, Professor of Medicine – Division of Endocrinology, Metabolism and Diabetes, and Cardiology, University of Colorado, Anschutz Medical Campus, at the recent AACE Meeting.

Dr. Eckel — who has type 1 diabetes — discusses the complexity of treating diabetes, and how the use of these new PCSK9 inhibitors affects LDL and diabetes.


We can make a difference!


Dave Joffe, Editor-in-chief